The role of HER-2 expression in predicting response to therapy in breast cancer

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 11, 2000, Pages 46-52

  Mass, R ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION; GENES, ERBB-2; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 0034473776     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
2. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. Follow-up study of HER2/neu amplification in primary breast cancer
5. c-erbB-2 oncoprotein expression in primary and advanced breast cancer
6. HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
7. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
8. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
9. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group
10. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
11. Sensitivity of HER2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
12. Breast cancer
13. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
14. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
15. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and a reduced estrogen-dependence and tamoxifen-sensitivity in vivo
16. Epidermal growth factor receptor as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
17. Cell biological factors associated with the response of breast cancer to systemic treatment
18. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
19. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
20. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER2/neu protein
21. Elevated serum c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer
22. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
23. c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axiilary lymph node metastases
24. Tumor size, ploidy, S phase, and erbB-2 markers in patients with node-negative, ER-positive tumors: Findings fron NSABP B-14
25. Lack of interaction of tamoxifen use and ERbB-2/heu expression in CALGB 8541
26. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
27. Prognostic importance of c-erbB-2 expression in breast cancer
28. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
29. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
30. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
31. ERB-B2 overexpression and response to chemotherapy-NSABP study B15
32. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressmg metastatic breast cancer that has progressed after chemotherapy for metastatic disease
33. Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases antlcancer activity: A randomized multinational controlled phase III trial